VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
SNWV
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
SNWVSANUWAVE Health, Inc.
$10.82$93M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

SNWV logoSANUWAVE Health, Inc.(SNWV)Earnings, Financials & Key Ratios

SNWV•NASDAQ
$10.82
26.4× P/E·Price updated Jul 7, 2026
SectorHealthcareIndustryMedical DevicesSub-IndustryAesthetics, dermatology, and wound care
AboutSANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.Show more
  • Revenue$44M+35.0%
  • EBITDA$6M-5.1%
  • Net Income$12M+137.7%
  • EPS (Diluted)0.41+105.8%
  • Gross Margin77.11%+2.5%
  • EBITDA Margin14.14%-29.7%
  • Operating Margin11.23%-32.4%
  • Net Margin26.82%+127.9%
  • ROE729.65%

SNWV Price & Volume

SANUWAVE Health, Inc. (SNWV) stock price & volume — 10-year historical chart

Loading chart...

Volatile Revenue Growth Masks Structural Margin Stability

Investment Thesis • Updated 2026Q1

VerdictNeutral
Growth:Mixed
Profitability:Moderate
Financial:Vulnerable
Cash Flow:Mixed
Primary Risk:Regulatory and reimbursement dependency

Key Thesis Takeaways

  • SANUWAVE Health demonstrates a high-margin business model with gross margins consistently near 77%, yet the firm faces significant challenges in achieving scalable operating profitability.
  • While the company has successfully transitioned from a $60.3M negative equity position in 2024Q3 to a positive $1.8M by 2026Q1, the reliance on non-operating gains and volatile working capital cycles complicates long-term valuation.
  • Investors should monitor the sustainability of revenue growth, which decelerated to 3.0% in 2026Q1, alongside the company's ability to manage its $7.2M debt load without further dilutive financing.

Verdict Logic

while the company has improved its current ratio to 1.31 as of 2026Q1, the erratic free cash flow trajectory and reliance on non-operating items to support a 21.00 P/E multiple warrant a cautious, wait-and-see approach.

SNWV Growth Metrics

SANUWAVE Health, Inc. (SNWV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years46.53%
5 Years61.12%
3 Years38.05%
TTM22.49%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM149.35%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM111.39%

Return on Capital

10 Years147.93%
5 Years147.93%
3 Years147.93%
Last Year136.04%

SNWV Recent Earnings

SANUWAVE Health, Inc. (SNWV) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 2/12 qtrs (50%)●Beat Revenue 2/12 qtrs (50%)
Q2 2026Latest
May 12, 2026
Metric
Actual
Est
EPS
$0.17-21.4%
$0.14
Rev
$10M+0.2%
$10M
Q2 2026
Mar 26, 2026
Metric
Actual
Est
EPS
$0.03-82.4%
$0.17
Rev
$13M+1.1%
$13M
Q4 2025
Nov 7, 2025
Metric
Actual
Est
EPS
$0.46+43.8%
$0.32
Rev
$11M-13.4%
$13M
Q3 2025
Aug 8, 2025
Metric
Actual
Est
EPS
$0.01+111.1%
$0.09
Rev
$10M-18.8%
$13M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 12, 2026
$0.17vs $0.14-21.4%
$10Mvs $10M+0.2%
Q2 2026Mar 26, 2026
$0.03vs $0.17-82.4%
$13Mvs $13M+1.1%
Q4 2025Nov 7, 2025
$0.46vs $0.32+43.8%
$11Mvs $13M-13.4%
Q3 2025Aug 8, 2025
$0.01vs $0.09+111.1%
$10Mvs $13M-18.8%
Based on last 12 quarters of dataView full earnings history →

Latest SNWV News

Recent stock market news and headlines for SANUWAVE Health, Inc. (SNWV)

GlobeNewsWire·Jun 16, 2026
Sanuwave Health Updates Second Quarter 2026 Guidance

Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million Company on pace for record unit sales of applicators in Q2 Market disruption impacting Ultramist system sales EDEN PRAIRIE, Minn., June 16, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in advanced wound care, today announced that revenues for the second quarter of 2026 are expected to be in the range of $8.5 to $9.5 million, below the guidance provided on the Q1 earnings call on May 13 of this year.

Peers Comparison

Key metrics vs top competitors for SANUWAVE Health, Inc. (SNWV)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
SNWV logoSNWVSANUWAVE Health, Inc.Current
$10.82$93.04M26.3934.98%26.82%729.65%—
MLSS logoMLSSMilestone Scientific Inc.
$0.34$29.71M-4.823.99%-51.3%-166.28%—
XTNT logoXTNTXtant Medical Holdings, Inc.
$0.42$58.84M13.9814.21%1.5%3.68%—
LNTH logoLNTHLantheus Holdings, Inc.
$103.41$6.73B30.330.5%18.05%24.33%—
NVCR logoNVCRNovoCure Limited
$17.72$2.02B-14.528.28%-25.66%-50.82%—
ANIK logoANIKAnika Therapeutics, Inc.
$15.87$212.67M-20.88-5.91%-9.52%-7.74%—

Compare SNWV vs Peers

SANUWAVE Health, Inc. (SNWV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs MLSS

Most directly comparable listed peer for SNWV.

Scale Benchmark

vs DXCM

Larger-name benchmark to compare SNWV against a more recognizable public peer.

Peer Set

Compare Top 5

vs MLSS, XTNT, LNTH, NVCR

SNWV SEC Filings & Documents

SANUWAVE Health, Inc. (SNWV) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 12, 2026·SEC

Material company update

Apr 16, 2026·SEC

Material company update

Mar 26, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 26, 2026·SEC

FY 2025

Mar 20, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

May 12, 2026·SEC

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 7, 2025·SEC

Get notified when SNWV posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

SNWV Frequently Asked Questions

SANUWAVE Health, Inc. (SNWV) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is SANUWAVE Health, Inc.'s revenue?

SANUWAVE Health, Inc. (SNWV) reported $44.3M in revenue for fiscal year 2025.

How fast is SANUWAVE Health, Inc. growing?

SANUWAVE Health, Inc. (SNWV) grew revenue by 35.0% over the past year. This is strong growth.

Is SNWV profitable?

Yes, SANUWAVE Health, Inc. (SNWV) is profitable, generating $16.1M in net income for fiscal year 2025 (26.8% net margin).

Dividend & Returns
What is SNWV's return on equity?

SANUWAVE Health, Inc. (SNWV) has a return on equity (ROE) of 729.6%. This is excellent, indicating efficient use of shareholder capital.

What is SANUWAVE Health, Inc.'s free cash flow?

SANUWAVE Health, Inc. (SNWV) generated $5.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in SNWV back in 2006?

Total return calculator · dividends reinvested · 20+ years of data

See returns →